Therapie eines schweren gemischten Handekzems und generalisierten Ekzems mit dem JAK‐Inhibitor Upadacitinib
Open Access
- 8 January 2025
- journal article
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (1) , 93-96
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitorsFrontiers in Immunology, 2023
- Effect of upadacitinib on atopic hand eczema in patients with moderate‐to‐severe atopic dermatitis: Results from two randomized phase 3 trialsJournal of the European Academy of Dermatology and Venereology, 2023
- Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registryContact Dermatitis, 2023
- A case of erythrodermic mycosis fungoides responding to upadacitinibJAAD Case Reports, 2022
- A Case of Tofacitinib-Induced Lymphomatoid Papulosis With Ocular InvolvementThe American Journal of Dermatopathology, 2022
- The pan‐JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase IIb trial*British Journal of Dermatology, 2022
- A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomasBlood, 2021
- Guidelines for diagnosis, prevention, and treatment of hand eczemaContact Dermatitis, 2021
- Prevalence, incidence, and severity of hand eczema in the general population – A systematic review and meta‐analysisContact Dermatitis, 2021
- Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double‐blind, vehicle‐controlled phase II a studyBritish Journal of Dermatology, 2019